Technical Data Sheet
Cagrilintide
Also Known As: AM833, Cagrilintide AM833, Long-acting amylin analog, Amylin receptor agonist, Calcitonin receptor agonist obesity, Amylin obesity peptide, Pramlintide analog long-acting, Amylin analog cagrilintide, Novo Nordisk amylin, Cagrilintide weekly injection, amylin analog, amylin receptor agonist, cagri
Scan To View Profile
| Evidence Tier | Investigational |
|---|---|
| Category | Weight Loss & Metabolism |
| Class | Long-acting synthetic amylin analog (fatty acid-conjugated for once-weekly dosing) |
| Molecular Target | Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation |
| Sequence | acylated cyclic amylin analog |
| Molecular Weight | ~4.4 kDa |
| CAS | 1415456-99-3 |
| Parent | Human amylin |
| Mechanism | It perfectly copies a natural hormone called amylin. It connects to the brain's hunger center and forces it to slow down the emptying of your stomach, keeping you full. |
| Studied For | Obesity / overweight, Type 2 diabetes, Combination with semaglutide (CagriSema), Amylin receptor agonism for satiety, Caloric intake reduction, Body weight reduction, Glucagon suppression, Gastric emptying delay, Amylin-mediated satiety signaling, Cardiometabolic risk reduction, Insulin sensitivity improvement, Metabolic syndrome, weight loss, satiety, appetite suppression, gastric emptying slowing, obesity |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | bacteriostatic or sterile water |
| Storage Temperature | frozen/refrigerated, dark |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Cyclic disulfide; avoid reducing conditions. |
| Regulatory | Investigational (Novo Nordisk); not FDA-approved as a single agent. It is the amylin analogue component of CagriSema, which is under FDA review following a December 2025 NDA filing. Not on the WADA 2026 Prohibited List. |
| Sources |